3Schelbert HR et al. J Nucl Med 1998,139:1302-1305.
4Engel H et al, J Nucl Med,1996,37:441-446.
5Conti PS. Cancer Invest,1995,13:244-259.
6Marco Pagani,Sharon Stone-Elander,Stig A. Larsson. Alternative positron emission tomography with non-conventional positron emitters: effects of their physical properties on image quality and potential clinical applications[J] 1997,European Journal of Nuclear Medicine(10):1301～1327
7Michael Zimny,Roland Bares,Jürgen Fa?,Gerhard Adam,Uwe Cremerius,Bernhard Dohmen,Peter Klever,Osama Sabri,Volker Schumpelick,Udalrich Buell. Fluorine-18 fluorodeoxyglucose positron mission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases[J] 1997,European Journal of Nuclear Medicine(6):678～682
8P. Rigo,P. Paulus,B. J. Kaschten,R. Hustinx,T. Bury,G. Jerusalem,T. Benoit,J. Foidart-Willems. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose[J] 1996,European Journal of Nuclear Medicine(12):1641～1674
9Ludwig G. Strauss. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients[J] 1996,European Journal of Nuclear Medicine(10):1409～1415
10Terry Jones. The role of positron emission tomography within the spectrum of medical imaging[J] 1996,European Journal of Nuclear Medicine(2):207～211
